The FDA has accepted an investigational new drug application for Brimochol, according to a press release from Visus Therapeutics.
Brimochol (carbachol and brimonidine tartrate) is a once-daily eye drop to correct the loss of near vision from presbyopia, the release said. Visus will now begin a phase 2 clinical trial in the U.S.
“We are excited to begin dosing patients in the phase 2 clinical study, which we believe will validate Brimochol as a well-tolerated solution that meets patients’ desire for a long-lasting near vision treatment option,” Ben Bergo, co-founder and CEO of
Uncategorized